When the stock market took a nosedive in early October, Shervin Pishevar 21-hour tweetstorm didn’t seem as strange as it was a few months ago. Investors who follow Pishevar realized that the former CEO of Sherpa Capital wasn’t losing his mind. A sudden stock market drop of 800 points can rattle the nerves of any investor. Some investors thought Shervin Pishevar was angry when he tweeted the stock market would drop by 6,000 points in the coming months. He angrily left the investment company he founded at the end of 2017, and he fell off the radar until he surfaced via his now-famous tweet rant.
Shervin Pishevar is a force to reckon with in the investment industry. His track record for picking startups that turn into cash cows is impressive. Shervin didn’t hesitate when he found Uber. He quickly put $26 million into the new care service, and as everyone knows that venture capital deal paid off. When Airbnb came on the scene, Shervin Pishevar was at the front of the investment line with millions to invest. Pishevar’s list of profitable investments made him a superstar in Silicon Valley. But during that famous tweetstorm, Shervin Pishevar threw Silicon Valley a curveball. Pishevar told investors that his pals in Silicon Valley weren’t as sharp as they were ten years. Shervin thinks the Valley is on the way down in terms of being the startup capital of the world.
Mr. Pishevar also gave the bond market bad reviews during his tweeting extravaganza. The bond market won’t save investors when the big stock market crash materializes, according to Shervin Pishevar. That recent blink-of-an-eye 800-point drop was enough to make any investor reread Pishevar’s tweets. Now that the Feds are raising interest rates, and the stock market is acting like a giant roller-coaster, bond investors are looking for alternative investments. Gold seems to be the best choice. Pishevar tweet about the stability of gold prices gave investors a viable alternative.
The stock market came back from that 800-point drop, but investors now know Pishevar’s tweetstorm is no joke. More investors think the market will adjust itself in 2019 thanks to Pishevar’s tweetstorm.
Shervin Pishevar is one of the most respected figures in the world of tech finance. He has also emerged over the last few years as one of the most outspoken critics of tech monopolies in the United States. Shervin Pishevar has repeatedly warned that the U.S. tech monopolies are rapidly approaching the point where they are eclipsing the power of any monopolies that have come before them. Pishevar says that when companies such as Standard Oil, U.S. Steel and Ma Bell threatened the stability of the nation’s economy through their iron grip over critical infrastructure, they were broken up by the government. Now, Shervin Pishevar warns that the government itself may be so thoroughly captured by the monopolies that it may be losing its power to act. This, he says, could ultimately lead to economic disaster.
Amazon: private profits and public costs
Shervin Pishevar points out that anyone who still harbors doubts as to the extreme power that some of the tech monopolies currently wield over the nation should turn to the example of Amazon. As its recent competition to see where it would locate its second headquarters has roundly illustrated, local and state governments from coast to coast are willing to write into law deep and special exemptions just for the opportunity to have the tech giant grace their landscapes.
But it isn’t just the company’s ability to effectively dodge taxes by simply telling states that they have to pay to play with the firm. Amazon’s entire business model, says Shervin Pishevar, has been built around its ability to use the highly subsidized U.S postal system. Pishevar says that the U.S. Post Office, from a business perspective, is an intractable disaster. The Post Office loses billions upon billions of dollars each year. That is how it’s able to deliver packages and letters so cheaply. But without that ability to have taxpayer-subsidized cheap and effective delivery methods, Amazon probably wouldn’t even exist.
Shervin Pishevar says that Amazon not only doesn’t have to reimburse the post office, it is now dodging the majority of its taxes through antics like its corporate HQ bidding competition.
Technology is always advancing, especially in the field of medicine as new cures and treatments are always in the works. Unfortunately, like any other business out there, things are not always what they seem. This looks like the case for a Biotech company that has introduced a new medical treatment for patients to fight cystic fibrosis. Kerrisdale Capital has issued a negative report on said Biotech company with the backing of Sahm Adrangi, Kerrisdale Founder, and CEO. As a leading investment company and one of the most reputable investors in the country, Sahm Adrangi is often heard about and listen to for his insight.
Proteostasis is the Biotech company that Sahm Adrangi is currently calling into question, as he doesn’t believe their medical research was thorough and even reviewed to the maximum extent. Kerrisdale managed to get a closer look into the biotech company and has determined that their research and claims have not be done on an adequate sample sizing since they only had four patients for testing. What Sahm found was that during the trial period for their testing, these four patients experience severe drops in their overall lung performance. With such a small sample size and data that looks sloppy and certainly not finished, Kerrisdale is calling Proteostasis claims into question.
Sahm Adrangi has invested in many companies over the course of his career and to tremendous success because of his insight and deep research protocols. Before investing in a company or letting others know a company is safe, Sahm takes the time to truly dig into a company. This is how he found Proteostasis’s supposed breakthrough was actually much less than what it seemed at the surface. According to the report from Kerrisdale, there are no results to be found through the biotech company’s data. Also, should the biotech company’s drug fail to work, they stand to lose virtually all of their assets, so the desire to produce profits is extremely high. After the initial Kerrisdale report on Proteostasis, the biotech company’s share value fell more than 15 percent.